Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Beth E. Dunning"'
Autor:
James E. Foley, Michael Camilleri, Monica Ligueros Saylan, Denise Serra, Beth E. Dunning, Gerlies Bock, Robert A. Rizza, D. Burton, Paula D. Giesler, Adrian Vella
Publikováno v:
Diabetes. 56:1475-1480
OBJECTIVE— We sought to determine whether alterations in meal absorption and gastric emptying contribute to the mechanism by which inhibitors of dipeptidyl peptidase-4 (DPP-4) lower postprandial glucose concentrations. RESEARCH DESIGN AND METHODS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::215b02eeb31509056ecf966693a71a7a
https://doi.org/10.2337/db07-0136
https://doi.org/10.2337/db07-0136
Autor:
Yan-Ling He, Carolyn F. Deacon, James E. Foley, Julie M. Bullock, Monica Ligueros-Saylan, Beth E. Dunning, Yibin Wang, Jens Juul Holst
Publikováno v:
The Journal of Clinical Pharmacology. 47:633-641
This randomized, open-label, placebo-controlled, 7-period crossover study assessed dose-response relationships following single oral doses (10-400 mg) of vildagliptin in 16 patients with type 2 diabetes mellitus. Plasma levels of parent drug, dipepti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1f73514fe255583e689e44127f50ccd
https://doi.org/10.1177/0091270006299137
https://doi.org/10.1177/0091270006299137
Autor:
Beth E. Dunning, John E. Gerich
Publikováno v:
Endocrine Reviews. 28:253-283
The hyperglycemic activity of pancreatic extracts was encountered some 80 yr ago during efforts to optimize methods for the purification of insulin. The hyperglycemic substance was named "glucagon," and it was subsequently determined that glucagon is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f22fcebe8da3e869b0050f3f839839d
https://doi.org/10.1210/er.2006-0026
https://doi.org/10.1210/er.2006-0026
Autor:
Yan-Ling He, James E. Foley, Jens J. Holst, Andrea Mari, Bogdan Balas, Ralph A. DeFronzo, Muhammad R. Baig, Catherine Watson, Celia Darland, Beth E. Dunning, Carolyn F. Deacon, Monica Ligueros-Saylan, Kenneth Cusi, Yibin Wang
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 92:1249-1255
Vildagliptin is a selective dipeptidyl peptidase IV inhibitor that augments meal-stimulated levels of biologically active glucagon-like peptide-1. Chronic vildagliptin treatment decreases postprandial glucose levels and reduces hemoglobin A1c in type
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92cddb8bc1c4c4e558aead060322c0a2
https://doi.org/10.1210/jc.2006-1882
https://doi.org/10.1210/jc.2006-1882
Publikováno v:
Diabetologia. 48:1700-1713
Although there is abundant evidence that hyperglucagonaemia plays a key role in the development of hyperglycaemia in type 2 diabetes, efforts to understand and correct this abnormality have been overshadowed by the emphasis on insulin secretion and a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49359ecb9f28321711fa2db0df430cf3
https://doi.org/10.1007/s00125-005-1878-0
https://doi.org/10.1007/s00125-005-1878-0
Publikováno v:
Diabetologia. 46:M37-M43
Nateglinide, a D-phenylalanine derivative, belongs to a new group of insulinotropic agents with rapid onset and short duration of action. These agents have been developed to reduce the risk of hypoglycaemia associated with pharmacological control and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba6772a574a1d51705dee6c929621dd9
https://doi.org/10.1007/s00125-002-0935-1
https://doi.org/10.1007/s00125-002-0935-1
Autor:
Melanie Scott, Doss W. Neal, Alan D. Cherrington, Tadasu Ikeda, Mary Courtney Moore, Beth E. Dunning
Publikováno v:
Metabolism. 51:1324-1330
We sought to determine whether an incretin effect could be observed when glucose was infused via the hepatic portal (Po) vein versus a peripheral (Pe) vein. Identical hyperglycemia (155 [plusmn] 7 and 154 [plusmn] 8 mg/dL, respectively) was produced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e1b5266c32b81ab1973ae465fd5a4cb
https://doi.org/10.1053/meta.2002.34712
https://doi.org/10.1053/meta.2002.34712
Autor:
Edwin Bernard Villhauer, Thomas Edward Hughes, John A Brinkman, Manisha Mone, Bonnie L Mangold, Mary E Russell, Goli B Naderi, Stephen Craig Weldon, Beth E. Dunning
Publikováno v:
Journal of Medicinal Chemistry. 45:2362-2365
Dipeptidyl peptidase IV (DPP-IV) inhibition has the potential to become a valuable therapy for type 2 diabetes. We report the first use of solid-phase synthesis in the discovery of a new DPP-IV inhibitor class and a solution-phase synthesis that is p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1a23159d1dca769374d0d90eb53fdcb
https://doi.org/10.1021/jm025522z
https://doi.org/10.1021/jm025522z
Publikováno v:
Current Pharmaceutical Design. 7:1375-1397
The loss of early insulin secretion appears to be a critical event in the deterioration in glucose tolerance during the development of type 2 diabetes. There is therefore a strong rationale for developing new antidiabetic agents aimed at restoring or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3752b9a514103c03122c2a589e34ea0
https://doi.org/10.2174/1381612013397348
https://doi.org/10.2174/1381612013397348
Autor:
Hongjie Zheng, M. Gatlin, James E. Foley, Sherwyn Schwartz, Priscilla Hollander, Stephen J. Haas, Beth E. Dunning
Publikováno v:
Diabetes Care. 24:983-988
OBJECTIVE—This study compared the effects of nateglinide, glyburide, and placebo on postmeal glucose excursions and insulin secretion in previously diet-treated patients with type 2 diabetes. RESEARCH DESIGN AND METHODS—This randomized, double-bl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2c1da37fbde2d092db8ec079b5cd367
https://doi.org/10.2337/diacare.24.6.983
https://doi.org/10.2337/diacare.24.6.983